Oculis Holding AG (OCS) Form 6-K — May 29, 2026
Oculis Holding AG announced that its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 in diabetic macular edema failed to meet the primary endpoint of mean change in best corrected visual acuity at Week 52. Consequently, the company stated it does not plan to pursue an FDA regulatory filing for OCS-01 in this indication, effectively ending development of this asset for DME. Despite the clinical failure, OCS-01 demonstrated a substantial and persistent reduction in retinal thickness compared to vehicle, and the safety profile was consistent with previous trials.
Key figures
- Cash Position
- 278000000
- Cash runway
- into 2H 2029
- Patients enrolled
- Over 800
- Cst change diamond1 ocs01
- -51.8 micrometers
- Cst change diamond2 ocs01
- -64.3 micrometers
- Bcva change diamond1 ocs01
- 1.2 letters
- Bcva change diamond2 ocs01
- 4.6 letters
- Cst change diamond1 vehicle
- -31.7 micrometers
- Cst change diamond2 vehicle
- -18.8 micrometers
- Bcva change diamond1 vehicle
- 5.1 letters
- Bcva change diamond2 vehicle
- 5.2 letters
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.